Journal
JOURNAL OF CANCER
Volume 12, Issue 2, Pages 508-517Publisher
IVYSPRING INT PUBL
DOI: 10.7150/jca.50575
Keywords
Denosumab; Giant-cell Tumor of Bone; Local recurrence; Meta-analysis
Categories
Funding
- National Natural Science Foundation of China [81972509]
Ask authors/readers for more resources
This systematic review and meta-analysis showed that preoperative denosumab may increase the risk of local recurrence in patients with GCTB treated with curettage. Caution should be taken when using denosumab in the management of GCTB.
Objective: This systematic review and meta-analysis aimed to determine the effect of preoperative denosumab on the local recurrence of giant-cell tumor of bone (GCTB) treated with curettage. Methods: PubMed, Embase, Cochrane Library, and Web of Science were comprehensively searched. The following data were analyzed using meta-analysis: local recurrence rate of patients receiving denosumab followed by curettage (denosumab group), local recurrence rate of patients receiving curettage only (control group), and a comparison of the local recurrence rates of the two groups. Results: Nine studies that contained 672 patients with GCTB were included in this review. Patients in the denosumab group (preoperative denosumab followed by curettage) had a higher risk of local recurrence compared with those in the control group (curettage only) (odds ratio = 3.04, 95% confidence interval = 1.48-6.22, P < 0.01). The association between preoperative denosumab and local recurrence remained significant in most of the subgroup analyses, except for those with sample sizes < 59 (P = 0.09), sacral GCTB (P = 0.42), and usage of postoperative denosumab (P = 0.38). Conclusions: Preoperative denosumab may increase the risk of local recurrence of GCTB treated with curettage and should be used with caution in the management of GCTB.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available